AxoGen Q3 2026 slides: revenue surges 26%, breast growth accelerates

The summary of this story is being written. Until it is ready, this page shows the lead article's headline and summary.

Axogen, Inc. raised its 2026 revenue outlook to at least $290M, marking a 29% growth. The company expects $7M from BioCircuit, with organic revenue of at least $283M and a gross margin of 73% or more. Axogen also anticipates positive free cash flow for the year, according to the company.

Summary pending. Not investment advice. Figures are as stated by the linked sources.